Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: Role of common γ-chain cytokines

Journal of Immunology

Volumn 171, Issue 4, 2003, Pages 2134-2141

  Anichini, Andrea ^a   Scarito, Alessia ^a   Molla, Alessandra ^a   Parmiani, Giorgio ^a   Mortarini, Roberta ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOTOXIC FACTOR; GRANZYME B; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; PERFORIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MATURATION; CLUSTER ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; EFFECTOR CELL; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; MEMORY CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR DIFFERENTIATION;

EID: 0042123664     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.4.2134     Document Type: Article

References (35)

1. Rosenberg, S. A. 2001. Progress in human tumour immunology and immunotherapy. Nature 411:380.
2. Houghton, A. N., J. S. Gold, and N. E. Blachere. 2001. Immunity against cancer: lessons learned from melanoma. Curr. Opin. Immunol. 13:134.
3. Kaech, S. M., E. J. Wherry, and R. Ahmed. 2002. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2:251.
4. Yee, C., S. R. Riddell, and P. D. Greenberg. 2001. In vivo tracking of tumor-specific T cells. Curr. Opin. Immunol. 13:141.
5. + T cells. J. Exp. Med. 186:1407.
6. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708.
7. Champagne, P., G. S. Ogg, A. S. King, C. Knabenhans, K. Ellefsen, M. Nobile, V. Appay, G. P. Rizzardi, S. Fleury, M. Lipp, et al. 2001. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410:106.
8. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8:379.
9. + T cell response. J. Immunol. 168:5455.
10. + T cells. J. Exp. Med. 194:1711.
11. + memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 10:1182.
12. Wherry, E. J., V. Teichgraber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. Von Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4:225.
13. Dunbar, P. R., C. L. Smith, D. Chao, M. Salio, D. Shepherd, F. Mirza, M. Lipp, A. Lanzavecchia, F. Sallusto, A. Evans, et al. 2000. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J. Immunol. 165:6644.
14. - effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res. 62:1743.
15. Jager, E., H. Hohn, A. Necker, R. Forster, J. Karbach, K. Freitag, C. Neukirch, C. Castelli, R. D. Salter, A. Knuth, et al. 2002. Peptide-specific CD8+ T cell evolution in-vivo: response to peptide vaccination with melan-A/Mart-1. Int. J. Cancer 98:376.
16. + T cells by endogenous tumor antigen and peptide vaccines: a comparison to virus-specific T cells. Eur. J. Immunol. 32:731.
17. + T cells. J. Immunol. 168:5933.
18. Balch, C. M., A. C. Buzaid, S. J. Soong, M. B. Atkins, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton, Jr., J. M. Kirkwood, et al. 2001. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19:3635.
19. Anichini, A., A. Molla, R. Mortarini, G. Tragni, I. Bersani, M. Di Nicola, A. M. Gianni, S. Pilotti, R. Dunbar, V. Cerundolo, et al. 1999. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J. Exp. Med. 190:651.
20. Giacomini, P., P. Natali, and S. Ferrone. 1985. Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. J. Immunol. 135:696.
21. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivolfini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
22. Valmori, D., J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard, D. Rimoldi, V. Jongeneel, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/Mart-1 immunodominant peptide analogues. J. Immunol. 160:1750.
23. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
24. Van der Bruggen, P., J. Bastin, T. Gajewski, P. G. Coulie, P. Boel, C. De Smet, C. Traversari, A. Townsend, and T. Boon. 1994. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24:3038.
25. Jager, E., Y. T. Chen, J. W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H. Wada, Y. Noguchi, E. Stockert, et al. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187:265.
26. Morrison, J., J. Elvin, F. Latron, F. Gotch, R. Moots, J. L. Strominger, and A. McMichael. 1992. Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. Eur. J. Immunol. 22:903.
27. Russo, C., A. K. Ng, M. A. Pellegrino, and S. Ferrone. 1983. The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells. Immunogenetics 18:23.
28. Eisen, M. B., P. T. Spellman, P. O. Brown, and D. Botstein. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95:14863.
29. Manjunath, N., P. Shankar, J. Wan, W. Weninger, M. A. Crowley, K. Hieshima, T. A. Springer, X. Fan, H. Shen, J. Lieberman, et al. 2001. Effector differentiation is not a prerequisite for generation of memory cytotoxic T lymphocytes. J. Clin. Invest. 108:871.
30. Tough, D. F., P. Borrow, and J. Sprent. 1996. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272:1947.
31. + T cells in vivo by IL-15. Immunity 8:591.
32. Pereno, R., J. Giron-Michel, A. Gaggero, E. Cazes, R. Meazza, M. Monetti, E. Monaco, Z. Mishal, C. Jasmin, F. Indiveri, et al. 2000. IL-15/IL-15Rα intracellular trafficking in human melanoma cells and signal transduction through the IL-15Rα. Oncogene 19:5153.
33. Lu, C., C. Sheehan, J. W. Rak, C. A. Chambers, N. Hozumi, and R. S. Kerbel. 1996. Endogenous interleukin 6 can function as an in vivo growth-stimulatory factor for advanced-stage human melanoma cells. Clin. Cancer Res. 2:1417.
34. Yue, F. Y., R. Dummer, R. Geertsen, G. Hofbauer, E. Laine, S. Manolio, and G. Burg. 1997. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int. J. Cancer 71:630.
35. Fehniger, T. A., M. A. Cooper, and M. A. Caligiuri. 2002. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev. 13:169.